Alvarez & Marsal (A&M) announced the appointments of James Guyton, Frank Orlowski and Rena Rosenberg, as Managing Directors within its rapidly expanding Life Sciences (LS) business unit. These strategic hires underscore A&M’s commitment to provide clients with the expertise for navigating life science industry complexities and capitalizing on growth opportunities.
With over five decades of combined experience, Mr. Guyton, Mr. Orlowski, and Ms. Rosenberg, deepen A&M’s bench strength in pharmaceuticals, biopharmaceuticals, medical devices, medical technology, and pharma services. Their addition reflects the firm’s investment in top-tier talent to help clients stay ahead of evolving regulatory demands, manage financial pressures, and unlock new avenues for sustained profitability.
“James, Frank, and Rena, bring a results-driven mentality and a wealth of experience aligned with A&M’s ‘leadership, action, results’ philosophy,” said Mark Freitas, Managing Director and Life Sciences Practice Leader. “Their appointments bolster our team and our ability to help life science clients achieve transformative growth.”
Mr. Guyton focuses on profitability enhancement, organizational transformation, and capability development for clients in the pharmaceuticals, biologics, vaccines, medical devices, diagnostics, contract services, distributors, and digital health sectors. His expertise helps clients drive profitability and growth while delivering products and services to meet patient needs. He has in-depth experience with operating model simplification, EBITDA expansion, cost reduction, pre-/post-deal mergers and acquisitions (M&A), product development, and portfolio management. Prior to joining A&M, Mr. Guyton served as a Managing Director at KPMG Strategy, leading performance improvement for that firm’s Healthcare & Life Sciences practice.
Mr. Orlowski possesses a deep understanding of global life science operations and finance, specializing in cost optimization, growth strategies, and M&A transactions. His experience across R&D, manufacturing, and distribution strengthens A&M’s ability to advise clients across various modalities and market segments. Prior to joining A&M, Mr. Orlowski served with Pfizer as an executive and advisor, leading finance, operations, and strategy across 35 individual global markets.
Ms. Rosenberg specializes in business strategy including from clinical development through launch, go-to-market, and growth and innovation and lifecycle management. She has worked in multiple sectors including branded and generic pharmaceuticals and MedTech, overseeing innovative strategies and translation into measurable results. Ms. Rosenberg has developed turnaround and growth strategies and marketing plans for 10+ multibillion-dollar products in retail and hospital environments. Prior to joining A&M, Ms. Rosenberg served as partner within McKinsey & Company’s North American Pharmaceuticals and Medical Devices Practice and co-founded that firm’s Digital Healthcare practice.
Tom Elsenbrook, Managing Director and Leader of A&M’s Corporate Performance Improvement group, said, “A&M’s integrated platform and global network of practitioners empower our Life Sciences team to address clients’ most pressing concerns. The addition of this talent trio strengthens our ability to meet the industry’s evolving needs, both today and in the future.”
Martin McGahan, a Managing Director and Head of Alvarez & Marsal’s Healthcare Industry Group (HIG) added, “The Life Sciences business unit exemplifies A&M’s collaborative approach. By seamlessly integrating diverse expertise from across the firm, we create a powerful advantage for solving clients’ complex problems and driving value throughout the healthcare ecosystem.”